Briefing on the Fundamentals of Summit Therapeutics

By Naomi Wentworth • Wednesday, November 20 15:16 • Permanent Link

Summit Therapeutics shares slid -7.8% this afternoon. Here's what you need to know about the Large-CapPharmaceutical company:

Summit Therapeutics has logged a 873.3% 52 week change, compared to 29.9% for the S&P 500
SMMT has an average analyst rating of buy and is -31.78% away from its mean target price of $27.03 per share
Its trailing earnings per share (EPS) is $-0.23, which brings its trailing Price to Earnings (P/E) ratio to -80.2. The Health Care sector's average P/E ratio is 26.07
The company's forward earnings per share (EPS) is $-0.38 and its forward P/E ratio is -48.5
The company has a Price to Book (P/B) ratio of 31.04 in contrast to the Health Care sector's average P/B ratio is 3.53
The current ratio is currently 9.3, which consists in its liquid assets divided by any liabilities due within in the next 12 months
The company's free cash flow for the last fiscal year was $-76888000 and the average free cash flow growth rate is -28.2%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.